December 10, 2021 – Page 7

Novartis data highlight efficacy of Piqray® in HR+/HER2- metastatic breast cancer with a PIK3CA driver mutation immediately post-CDK4/6i

Written by Customer Service on December 10, 2021. Posted in Public Companies.

New data underscore efficacy of Piqray, even in those patients with a short treatment duration on prior CDK4/6i or with ESR1 mutations, biomarkers of endocrine resistance1-5 Recent guideline updates support use of Piqray with fulvestrant for postmenopausal HR+/HER2- PIK3CA-mutated mBC patients immediately after failure on prior CDK4/6i treatment6 Piqray works synergistically with fulvestrant across the PI3K and estrogen receptor pathways, respectively—remaining the only treatment specifically approved for mBC with a PIK3CA mutation, a known oncogenic driver of the disease7–9 Five BYLieve presentations include data on longer-term follow-up and ESR1 mutations, which occur in up to 56% of patients with HR+/HER2- mBC1-5,10-11 Basel, December 10, 2021 — Novartis today announced new Piqray® (alpelisib) data indicating benefit...

Monarch Files Preliminary Short Form Base Shelf Prospectus for Future Growth Plans and Acquisitions

Written by Customer Service on December 10, 2021. Posted in Public Companies.

THIS NEWS RELEASE IS NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES MONTREAL, Dec. 10, 2021 (GLOBE NEWSWIRE) — MONARCH MINING CORPORATION (“Monarch” or the “Corporation”) (TSX: GBAR) (OTCQX: GBARF) announces that it has filed a preliminary short form base shelf prospectus (the “Preliminary Shelf Prospectus”) with the securities regulatory authorities in all the provinces of Canada (except the territories). Monarch has filed this Preliminary Shelf Prospectus to provide the Corporation with greater financial flexibility going forward but has not entered into any agreements or arrangements to authorize or offer any Securities (as defined below) at this time. Once a receipt for the final short form base shelf prospectus (the “Shelf Prospectus”) has been obtained from the applicable Canadian...

Scanfil revises its adjusted operating profit downwards and narrows the range of turnover for 2021

Written by Customer Service on December 10, 2021. Posted in Public Companies.

Scanfil plc Inside Information 10 December 2021 2.30 p.m. Scanfil revises its adjusted operating profit downwards and narrows the range of turnover for 2021 The downward revision of adjusted operating profit is mainly due to the continuation of challenges in material availability and the worsening of the COVID-19 situation in the company’s operating geographies during the fourth quarter of 2021. These matters have affected negatively productivity and profitability of the factories. In addition, the inventory growth has exposed the company to increasing foreign exchange risk. This has expected to have a higher negative effect during the last quarter of the year than anticipated. Customer demand has remained strong during the last quarter. New outlook for 2021: Scanfil estimates that its turnover for 2021 will be EUR 680–700 million,...

Relay Therapeutics Announces Preclinical Data that Support Clinical Development of RLY-2608 as Both a Single Agent and in Combination

Written by Customer Service on December 10, 2021. Posted in Public Companies.

RLY-2608 combines with standard of care therapies to drive regressions in ER+/HER2- breast cancer models CAMBRIDGE, Mass., Dec. 10, 2021 (GLOBE NEWSWIRE) — Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies, today shared additional preclinical data at the 2021 San Antonio Breast Cancer Symposium for RLY-2608, the first known allosteric, pan-mutant and isoform-selective PI3Kα inhibitor. The data presented in the poster help support the clinical development of RLY-2608 both in single agent and combination clinical trials for patients with PIK3CA (PI3Kα) mutant tumors, including PI3Kα-mutant, HR+/HER2- breast cancer. The data indicate RLY-2608 synergizes with fulvestrant and the CDK4/6 inhibitor...

Avicanna to Participate in the Lytham Partners Winter 2021 Investor Conference

Written by Customer Service on December 10, 2021. Posted in Public Companies.

TORONTO, Dec. 10, 2021 (GLOBE NEWSWIRE) — Avicanna Inc. (“Avicanna” or the “Company”) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN), a biopharmaceutical company focused on the development, manufacturing, and commercialization of plant-derived cannabinoid-based products, announced today it will be participating in the Lytham Partners Winter 2021 Investor Conference taking place from December 13-16, 2021. During the event, the company will be participating in a webcasted Fireside Chat discussing its vision for 2022 and conducting 1×1 virtual investor meetings. The webcasted Fireside Chat will be available for viewing at 11:00am ET on Monday, December 13, 2021, on https://wsw.com/webcast/lytham3/avi/1858880. The webcast will also be available for replay following the event. To arrange a 1×1 meeting with management,...

Cytokinetics Announces Data From Its ALS Program Presented at the 32nd International Symposium on ALS/MND

Written by Customer Service on December 10, 2021. Posted in Public Companies.

Majority of Initial Patients Enrolled in COURAGE-ALS Show Intended Middle to Fast Disease Progression Phenotype at Baseline SOUTH SAN FRANCISCO, Calif., Dec. 10, 2021 (GLOBE NEWSWIRE) — Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that new data were presented at the 32nd International Symposium on ALS/MND including an analysis of baseline characteristics from the initial patients enrolled in COURAGE-ALS (Clinical Outcomes Using Reldesemtiv on ALSFRS-R in a Global Evaluation in ALS), the ongoing Phase 3 clinical trial of reldesemtiv in patients with amyotrophic lateral sclerosis (ALS). In addition, supplemental analyses from FORTITUDE-ALS (Functional Outcomes in a Randomized Trial of Investigational Treatment with CK-2127107 to Understand Decline in Endpoints – in ALS), the Phase 2 clinical trial of reldesemtiv in ALS,...

CareTrust REIT Announces David Sedgwick to Succeed Greg Stapley as Chief Executive Officer

Written by Customer Service on December 10, 2021. Posted in Public Companies.

SAN CLEMENTE, Calif., Dec. 10, 2021 (GLOBE NEWSWIRE) — The Board of Directors of CareTrust REIT, Inc. (Nasdaq:CTRE) today announced the appointment of David Sedgwick as Chief Executive Officer, to be effective as of January 1, 2022. Mr. Sedgwick will succeed founding Chairman and CEO Greg Stapley, who will continue to serve as CareTrust’s Executive Chairman during an approximately six-month transition period, following which he and his wife Deborah will commence a three-year, full-time volunteer assignment for The Church of Jesus Christ of Latter-day Saints. The Board also announced that Diana M. Laing has been appointed as Lead Independent Director. Mr. Sedgwick, who has been with CareTrust since 2014, currently serves as CareTrust’s President and Chief Operating Officer and will retain his title as the Company’s President. Prior...

Form 8.3 – [Clinigen Group plc – 09 12 2021] – (CGWL)

Written by Customer Service on December 10, 2021. Posted in Mergers And Acquisitions.

FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORERule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a) Full name of discloser: CANACCORD GENUITY WEALTH LIMITED (b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named. N/A (c) Name of offeror/offeree in relation to whose relevant securities this form relates: Use a separate form for each offeror/offeree CLINIGEN GROUP PLC (d) If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree: N/A (e) Date position held/dealing undertaken: For...

Grant of stock options to managers

Written by Customer Service on December 10, 2021. Posted in Public Companies.

Company announcement No 26-2021 10 December 2021 With reference to company announcement no 08-18 of 24 August 2018 and pursuant to article 19(3) of EU Regulation 596/2014 of 16 April 2014 on market abuse (as amended) North Media A/S hereby announces the attached reporting of North Media A/S’ granting of stock options linked to the North Media-share to its managers. For further informationKåre Wigh, Group Executive Director & CFO, mobile +45 25 65 21 45 This document is an unofficial translation of the Danish original. In the event of any inconsistencies, the Danish version shall apply. Attachment 26-2021 ABJ Granting of stock options_UK_Dec 2021_

Kraig Biocraft Laboratories Spider Silk Featured on BBC Earth Series

Written by Customer Service on December 10, 2021. Posted in Public Companies.

Jon Rice, COO, Interview Clips Included in the Broadcast ANN ARBOR, Mich., Dec. 10, 2021 (GLOBE NEWSWIRE) — Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“the Company” or “Kraig Labs”), the leading developer of spider silk-based fibers, announces today that its spider silk was featured in a new episode of the BBC Earth’s “Inspired By Nature” series. To view a portion of the episode, please go to BBC Earth’s Facebook page and look for the “Bulletproof material made from a spider’s web” post at: https://www.facebook.com/bbcearth/videos/427557478860613/ “We don’t need to reinvent the wheel, we don’t need to try to do something better than nature has, we simply need to find ways to reproduce what nature has already done,” said Jon Rice to BBC Earth when asked where Kraig Labs draws its inspiration. Sample images of the Company’s...

Day: December 10, 2021

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Cookie Notice